EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration
LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.
September 29, 2022 @ 8 AM ET
Langham Hotel, NYC
LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.
Please join the company in-person or virtually as it hosts an event featuring:
- A Focal One Robotic focal HIFU introduction from EDAP's U.S. CEO
- A Urology Expert Panel Discussion with leading Prostate Cancer Experts
- A Live Focal One® Robotic Technology Demonstration
A live Q&A session will follow the formal presentations. To register for the event, please click here.
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as the length and severity of the COVID-19 pandemic, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
[email protected]
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected]
